According to this proteomic dataset, HMGCL was averaged approximately ~ 1.7-fold downregulated in HCC tumors, and samples with two fold down-regulation accounted for approximately 50.5% (51/101) in early-stage HCC patients (Supplementary Fig. S1B, C). Here, HMGCL is linked to hepatocellular carcinoma.